Drugs / 3,4-Methylenedioxymethamphetamine
3,4-Methylenedioxymethamphetamine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00895804 | Jun 2001 → Mar 2002 | mood disorder, substance-related disorder | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3,4-Methylenedioxymethamphetamine | “MDMA (3,4-Methylenedioxymethamphetamine, "Ecstasy") produces tachycardia, hypertension, hyperthermia, and other acute adverse effects.” NCT00895804 ↗ |
| Known as | Ecstasy | “MDMA (3,4-Methylenedioxymethamphetamine, "Ecstasy") produces tachycardia, hypertension, hyperthermia, and other acute adverse effects.” NCT00895804 ↗ |
| Known as | MDMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00895804 ↗ |